EyePoint Pharmaceuticals Inc (EYPT)
11.66
-0.40
(-3.32%)
USD |
NASDAQ |
Nov 04, 13:00
EyePoint Pharmaceuticals Total Liabilities (Quarterly): 95.94M for June 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | 95.94M |
March 31, 2024 | 79.31M |
December 31, 2023 | 88.86M |
September 30, 2023 | 101.42M |
June 30, 2023 | 118.39M |
March 31, 2023 | 76.20M |
December 31, 2022 | 83.99M |
September 30, 2022 | 84.14M |
June 30, 2022 | 82.07M |
March 31, 2022 | 77.74M |
December 31, 2021 | 78.99M |
September 30, 2021 | 75.50M |
June 30, 2021 | 71.96M |
March 31, 2021 | 71.43M |
December 31, 2020 | 73.18M |
September 30, 2020 | 69.20M |
June 30, 2020 | 65.50M |
March 31, 2020 | 63.82M |
December 31, 2019 | 64.64M |
September 30, 2019 | 63.13M |
June 30, 2019 | 63.12M |
March 31, 2019 | 61.98M |
September 30, 2018 | 41.15M |
June 30, 2018 | 59.98M |
March 31, 2018 | 41.96M |
Date | Value |
---|---|
December 31, 2017 | 4.292M |
September 30, 2017 | 4.326M |
June 30, 2017 | 5.341M |
March 31, 2017 | 4.995M |
December 31, 2016 | 4.984M |
September 30, 2016 | 10.48M |
June 30, 2016 | 10.74M |
March 31, 2016 | 9.612M |
December 31, 2015 | 9.526M |
September 30, 2015 | 8.637M |
June 30, 2015 | 8.999M |
March 31, 2015 | 7.855M |
December 31, 2014 | 7.905M |
September 30, 2014 | 7.938M |
June 30, 2014 | 7.747M |
March 31, 2014 | 7.675M |
December 31, 2013 | 8.22M |
September 30, 2013 | 8.498M |
June 30, 2013 | 8.549M |
March 31, 2013 | 7.879M |
December 31, 2012 | 7.232M |
September 30, 2012 | 7.176M |
June 30, 2012 | 6.961M |
March 31, 2012 | 7.278M |
December 31, 2011 | 7.155M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
63.82M
Minimum
Mar 2020
118.39M
Maximum
Jun 2023
80.12M
Average
77.74M
Median
Mar 2022
Total Liabilities (Quarterly) Benchmarks
Cassava Sciences Inc | 54.59M |
Adverum Biotechnologies Inc | 85.77M |
Regenxbio Inc | 221.11M |
Editas Medicine Inc | 152.79M |
Apellis Pharmaceuticals Inc | 640.16M |
Total Liabilities (Quarterly) Related Metrics
Total Assets (Quarterly) | 324.25M |
Shareholders Equity (Quarterly) | 228.30M |
Current Ratio | 4.749 |
Net Debt Paydown Yield | 1.53% |